02.10.2014 • News • chemical distributor • Brenntag • Mergers & Acquisitions (M&A)

Brenntag to Buy Italian Food Ingredients Supplier

German chemical distributor Brenntag plans to acquire Chimab, an Italian supplier of food ingredients and semi-finished products for several food subsectors including beverage, ice cream and desserts, meat and prepared foods.

The company based near Padua expects sales of more than €32 million for 2014.

Karsten Beckmann, CEO of Brenntag Europe, Middle East and Africa, said the acquisition will further increase the distributor's market penetration in Italy and provide more value-added services to new sectors within the food industry. It is a cornerstone and important contribution towards establishing and promoting the specialty business unit Food in Italy.

Brenntag expects the transaction to close before the end of 2014.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Top-Feature

most read

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.